Can allergy med stop bone pain in stem cell transplants?
NCT ID NCT05421416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the allergy drug loratadine can prevent bone pain caused by G-CSF, a medicine used to collect stem cells for transplant. About 78 adults with lymphoma or multiple myeloma will receive either loratadine or a placebo. The goal is to see if loratadine reduces pain severity and daily-life interference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Loratadine
- What this could lead to
- If it works, this could offer a simple, over-the-counter way to prevent bone pain during stem cell collection.
- What could go wrong
- This is a small, early-phase trial with only 78 participants, so results may not apply widely. Loratadine may not reduce pain better than a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cross Cancer Institute
RECRUITINGEdmonton, Alberta, T6G 1Z2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?